Department of Applied Tumour Biology, Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
Lancet Oncol. 2012 Jun;13(6):598-606. doi: 10.1016/S1470-2045(12)70109-2. Epub 2012 May 1.
BACKGROUND: Lynch syndrome is an inherited tumour predisposition syndrome caused by germline mutations of DNA mismatch repair (MMR) genes. Mutation carriers have a high risk of developing colorectal cancer, but do not present with polyposis, a typical feature of other colorectal cancer syndromes such as familial adenomatous polyposis, in which polyposis reflects the high frequency of biallelic APC gene inactivation. We asked whether in Lynch syndrome biallelic inactivation of MMR genes occurred at a similar frequency to that of APC gene, and whether MMR inactivation resulted in detectable lesions within the intestinal mucosa. METHODS: Resections done for small and large bowel cancer between January, 2002, and January, 2011, were retrieved. We systematically analysed non-tumorous mucosa from carriers of a Lynch syndrome mutation (set 1: ten patients) and control patients without Lynch syndrome (set 1: nine patients) for MMR protein expression (MLH1, MSH2, and EPCAM) with immunohistochemistry. We validated the findings in an independent sample set (set 2: 30 Lynch syndrome patients, 79 controls). We did an analysis of microsatellite instability by PCR analysis to test lesions for mismatch repair deficiency. We applied a Poisson regression model to analyse the distribution of MMR-deficient crypt foci counts and a Fisher's exact test to compare the prevalence of these foci between mutation carriers and control patients. FINDINGS: 20 crypt foci with no MMR protein expression were detected in 20·1 cm(2) of non-tumorous mucosa from Lynch syndrome patients (set 1), an additional five were detected upon resectioning of two samples. In an independent validation set (set 2), two MMR-deficient crypt foci were noted in 2·2 cm(2) of mucosa. No MMR-deficient crypt foci were noted in non-tumorous mucosa from control patients without evidence for Lynch syndrome (set 1: 3·7 cm(2), set 2: 4·8 cm(2)). Microsatellite instability was detected in all seven MMR-deficient crypt foci analysed. A subset of these foci displayed unusual architectural and cytological abnormalities, although they had no polypous or adenomatous appearance. INTERPRETATION: We identified a novel type of lesion, the MMR-deficient crypt focus, as the manifestation of biallelic MMR gene inactivation in Lynch syndrome. The abundance of MMR-deficient crypt foci indicates a high frequency of biallelic MMR gene inactivation, which is in sharp contrast with the low number of clinically manifest cancers in Lynch syndrome. This discrepancy suggests that most MMR-deficient crypt foci do not progress to cancer. We propose Lynch syndrome as a unique model syndrome for studying initial steps of MMR deficiency, tumour initiation and, possibly, elimination. FUNDING: German Cancer Aid and German Research Foundation.
背景:林奇综合征是一种遗传性肿瘤易感性综合征,由 DNA 错配修复(MMR)基因突变引起。突变携带者患结直肠癌的风险很高,但不会出现结直肠其他综合征(如家族性腺瘤性息肉病)的典型特征——息肉,而息肉反映了 APC 基因双等位基因失活的高频性。我们想知道在林奇综合征中,MMR 基因的双等位基因失活是否与 APC 基因的失活频率相似,以及 MMR 失活是否会导致肠黏膜内出现可检测到的病变。
方法:我们检索了 2002 年 1 月至 2011 年 1 月期间因小肠和大肠癌症而进行的切除术。我们使用免疫组织化学方法系统地分析了携带林奇综合征突变的患者(第 1 组:10 例)和无林奇综合征的对照患者(第 1 组:9 例)的非肿瘤黏膜中 MMR 蛋白表达(MLH1、MSH2 和 EPCAM)。我们在一个独立的样本组(第 2 组:30 例林奇综合征患者,79 例对照)中验证了这些发现。我们通过 PCR 分析进行微卫星不稳定性分析,以测试错配修复缺陷的病变。我们应用泊松回归模型分析 MMR 缺陷的隐窝焦点计数的分布,并使用 Fisher 精确检验比较突变携带者和对照患者中这些焦点的患病率。
结果:在林奇综合征患者的 20.1cm²非肿瘤黏膜中检测到 20 个具有 MMR 蛋白表达缺失的隐窝焦点(第 1 组),在两个样本的重新切除中又检测到另外 5 个。在一个独立的验证组(第 2 组)中,在 2.2cm²的黏膜中发现了 2 个 MMR 缺陷的隐窝焦点。在无林奇综合征证据的对照患者的非肿瘤黏膜中(第 1 组:3.7cm²,第 2 组:4.8cm²)未发现 MMR 缺陷的隐窝焦点。在分析的所有 7 个 MMR 缺陷的隐窝焦点中均检测到微卫星不稳定性。这些焦点中的一部分表现出不寻常的结构和细胞学异常,尽管它们没有息肉状或腺瘤样外观。
解释:我们发现了一种新的病变类型,即 MMR 缺陷的隐窝焦点,作为林奇综合征中 MMR 基因双等位基因失活的表现形式。MMR 缺陷隐窝焦点的丰度表明 MMR 基因双等位基因失活的高频性,这与林奇综合征中临床表现癌症的数量形成鲜明对比。这种差异表明,大多数 MMR 缺陷的隐窝焦点不会进展为癌症。我们提出林奇综合征作为研究 MMR 缺陷、肿瘤起始和可能消除的初始步骤的独特模型综合征。
资金:德国癌症援助和德国研究基金会。
Genes Chromosomes Cancer. 2011-10-27
Int J Cancer. 2015-4-1
Genes Chromosomes Cancer. 2009-8
Clin Genet. 2014-5
Nat Rev Clin Oncol. 2025-7-10
Cancers (Basel). 2024-10-12
Med Genet. 2023-12-5
Hematol Oncol Clin North Am. 2024-8
Cancers (Basel). 2024-2-20